The Role of P-cresol and Related Protein Fermentation Metabolites in Chronic Kidney Disease Patients
A Single Centre Observational Cohort Study on the Prognostic Relevance of P-cresol and Related Uremic Retention Solutes in the Development and/or Progression of Renal Failure and Cardiovascular Disease in Chronic Kidney Disease Patients
1 other identifier
observational
499
1 country
1
Brief Summary
Study on the natural history of uremic retention solutes in patients with mild-to-moderate chronic kidney disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2005
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2005
CompletedFirst Submitted
Initial submission to the registry
February 28, 2007
CompletedFirst Posted
Study publicly available on registry
March 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedMay 13, 2016
May 1, 2016
10.2 years
February 28, 2007
May 12, 2016
Conditions
Keywords
Interventions
effect of protein-bound uremic retention solutes
Eligibility Criteria
chronic kidney disease patients KDOQI stage 1-5 not yet on dialysis
You may qualify if:
- Informed consent
- Chronic kidney disease, stage 1-4 kDOQI
You may not qualify if:
- age below 18
- Kidney transplant recipient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universitaire Ziekenhuizen Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
Related Publications (3)
Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D. Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. Transplantation. 2016 Oct;100(10):2188-93. doi: 10.1097/TP.0000000000001311.
PMID: 27379556DERIVEDEvenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010 Jul;5(7):1268-76. doi: 10.2215/CJN.08241109. Epub 2010 May 6.
PMID: 20448073DERIVEDMeijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. 2010 Jul;5(7):1182-9. doi: 10.2215/CJN.07971109. Epub 2010 Apr 29.
PMID: 20430946DERIVED
Biospecimen
Serum, plasma Urine (if provided by patient)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Björn KI Meijers, MD
Universitaire Ziekenhuizen KU Leuven
- STUDY DIRECTOR
Pieter Evenepoel, MD, PhD
Universitaire Ziekenhuizen KU Leuven
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
February 28, 2007
First Posted
March 1, 2007
Study Start
October 1, 2005
Primary Completion
December 1, 2015
Study Completion
December 1, 2015
Last Updated
May 13, 2016
Record last verified: 2016-05
Data Sharing
- IPD Sharing
- Will not share